Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid LeukemiaPierre Fenaux, Lewis R. Silverman, C.L. Beach et al.|Journal of Clinical Oncology|2009Cited by 963
Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First RemissionAndrew H. Wei, Gail J. Roboz, Hartmut Döhner et al.|New England Journal of Medicine|2020Cited by 432
Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional careHartmut Döhner, Hervé Dombret, Anna Dolnik et al.|Leukemia|2018Cited by 136
The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First RemissionAndrew H. Wei, Gail J. Roboz, Hartmut Döhner et al.|Blood|2019Cited by 97
Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimensJohn F. Seymour, Hervé Dombret, Hartmut Döhner et al.|BMC Cancer|2017Cited by 73